Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512057 | 0.83 | CNR1 (0.59) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL30582486 | 0.82 | TRPA1 (0.64) | TRPA1CYP3A4TSHRHSD17B10IGF1R | |
| SCHEMBL157976 | 0.82 | TRPA1 (0.64) | TRPA1CYP3A4TSHRHSD17B10IGF1R | |
| 1,2-Dichlorobenzene SCHEMBL27793847 | 0.79 | TRPA1 (0.73) | TRPA1ALDH1A1CYP3A4HSD17B10TDP1 | |
| SCHEMBL2982854 | 0.79 | TTR (0.53) | ALDH1A1CYP3A4TSHRHSD17B10TDP1 | |
| SCHEMBL30290839 | 0.78 | TRPA1 (1.00) | TRPA1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL339841 | 0.78 | TRPA1 (0.73) | TRPA1ALDH1A1CYP3A4HSD17B10ALOX15 | |
| SCHEMBL93983 | 0.78 | IDO1 (0.58) | TRPA1ALDH1A1TSHRIGF1RALOX15 | |
| SCHEMBL56556 | 0.78 | TRPA1 (1.00) | TRPA1ALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL13791059 | 0.78 | CYP3A4 (0.47) | TRPA1ALDH1A1CYP3A4TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743406-B1 | TMEM16A MODULATORS | TMEM16A LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-9359349-B2 | Substituted quinazolines as kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2014-12-18 | — | — | US | disclosed |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | Intellikine, LLC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8779129-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2014-07-15 | — | — | US | disclosed |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA S.A. (CH) | 2013-05-16 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-20 | — | — | US | disclosed |
| US-8318733-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| CN-1298775-C | Naphthyltriazines as stabilizers for organic material | CIBA SC HOLDING AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| CN-1849343-A | Water-based concentrated product forms of light stabilizers prepared by heterophase polymerization techniques | CIBA SC HOLDING AG (CH) | 2006-10-18 | — | — | CN | disclosed |
| CN-1571814-A | Naphthyltriazines as stabilizers for organic materials | CIBA SC HOLDING AG (CH) | 2005-01-26 | — | — | CN | disclosed |
| CN-1224855-A | Photographic element containing water soluble bis Au(I) complexes | EASTMAN KODAK CO (US) | 1999-08-04 | — | — | CN | disclosed |
| CN-1132747-A | Bisresorcinyltriazines | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | TRPA1 4171/4885ALDH1A1 4725/4885CYP3A4 2041/4885 |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | TRPA1 1954/4885ALDH1A1 3954/4885CYP3A4 819/4885 |
| US-20140350248-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | TRPA1 2312/4885ALDH1A1 2519/4885CYP3A4 3027/4885 |
| US-20150141442-A1 | CHEMICAL ENTITIES AND THERAPEUTIC USES THEREOF | PIK3CA, PIK3CB, PIK3C3 | TRPA1 2312/4885ALDH1A1 2519/4885CYP3A4 3027/4885 |
| US-20140371223-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | TRPA1 337/4885ALDH1A1 3515/4885CYP3A4 1111/4885 |
| US-20120322798-A1 | Modulators of ATP-Binding Cassette Transporters | CFTR, ABCB1, ABCC2 | TRPA1 784/4885ALDH1A1 1991/4885CYP3A4 1141/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | TRPA1 1512/4885ALDH1A1 280/4885CYP3A4 512/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TRPA1 3839/4885ALDH1A1 1806/4885CYP3A4 708/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | TRPA1 4413/4885ALDH1A1 3050/4885CYP3A4 1226/4885 |
| US-20130123262-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | TRPA1 337/4885ALDH1A1 3515/4885CYP3A4 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.